Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171) has seen a nearly 4% increase in stock price following the announcement of a clinical collaboration with Dispatch Bio to initiate a Phase I clinical trial in China by 2026 for a combination therapy targeting solid tumors [1] Group 1: Company Developments - Kintor Pharmaceutical has partnered with Dispatch Bio, a biotechnology company that utilizes its proprietary Flare platform to develop treatments for solid tumors [1] - The planned Phase I clinical trial will evaluate the application of the combination therapy DISP-11 in patients with solid tumors [1] Group 2: Product Information - The combination therapy consists of Dispatch's investigational therapy, including the novel tumor-specific virus DV-10, and Kintor's targeted BCMA autologous CAR-T cell product, SaiKezai (Zevorikioran injection) [1] - SaiKezai has already received approval from the National Medical Products Administration (NMPA) in China for the treatment of multiple myeloma [1]
港股异动 | 科济药业-B(02171)涨近4% 近日宣布与Dispatch Bio达成合作 计划开展赛恺泽相关临床试验